Interferon alpha and rapamycin inhibit the growth of pheochromocytoma PC12 line in vitro

Endokrynologia Polska

Volumn 64, Issue 5, 2013, Pages 368-374

  Motylewska, Ewelina ^a   Lawnicka, Hanna ^a   Kowalewicz Kulbat, Magdalena ^b   Sicinska, Paulina ^b   Niedziela, Agata ^a   Melen Mucha, Gabriela ^a   Stepien, Henryk ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF LODZ   (Poland)

Author keywords

Antiangiogenic factors; Interferon alpha; PC12 line; Pheochromocytoma; Rapamycin

Indexed keywords

ALPHA INTERFERON; ENDOSTATIN; JV 1 36; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; SEMAXANIB; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; GROWTH HORMONE RELEASING FACTOR; INDOLE DERIVATIVE; JV 1-36; PYRROLE DERIVATIVE; VASCULOTROPIN A;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; NONHUMAN; PHEOCHROMOCYTOMA CELL; RAT; ADRENAL GLAND NEOPLASMS; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PC12 CELL LINE; PHEOCHROMOCYTOMA; TUMOR CELL CULTURE; VASCULARIZATION;

ADRENAL GLAND NEOPLASMS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; ENDOSTATINS; GROWTH HORMONE-RELEASING HORMONE; INDOLES; INTERFERON-ALPHA; NEOVASCULARIZATION, PATHOLOGIC; PC12 CELLS; PHEOCHROMOCYTOMA; PYRROLES; RATS; SIROLIMUS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84888859956     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: 10.5603/EP.2013.0020     Document Type: Article

References (42)

1. Tischler AS. Pheochromocytoma and extra-adrenal paraganglioma: updates. Arch Pathol Lab Med 2008; 132: 1272-1284.
2. Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giachè V, Mannelli M. Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol. 2012; 2012: 872713. DOI: 10.1155/2012/872713.
3. Konings IR, Verweij J, Wiemer EA et al. The applicability of mTOR inhibition in solid tumors. Curr Cancer Drug Targets 2009; 9: 439-450.
4. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
5. Zielke A, Middeke M, Hoffmann S et al. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery 2002; 132: 1056-1063.
6. Middeke M, Hoffmann S, Hassan I et al. In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor. Exp Clin Endocrinol Diabetes 2002; 110: 386-392.
7. Favier J, Plouin PF, Corvol P, Gasc JM. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol 2002; 161: 1235-1246.
8. Fassnacht M, Kreissl MC, Weismann D et al. New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther. 2009; 123: 117-141.
9. Grogan RH, Mitmaker EJ, Duh QY. Changing paradigms in the treatment of malignant pheochromocytoma. Cancer Control 2011; 18: 104-112.
10. Samant RS, Shevde LA. Recent advances in anti-angiogenic therapy of cancer. Oncotarget 2011; 2: 122-134.
11. Capdevila J, Salazar R, Halperín I et al. Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors. Cancer Metastasis Rev 2011; 30: S27-S34.
12. Siejka A, Lawnicka H, Melen-Mucha G et al. Antineoplastic action of growth hormone-releasing hormone (GHRH) antagonists. Recent Pat Anticancer Drug Discov 2012; 7: 56-63.
13. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315: 971-979.
14. Turner HE, Harris AL, Melmed S et al. Angiogenesis in endocrine tumors. Endocr Rev 2003; 24: 600-632.
15. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
16. Xie L, Duncan MB, Pahler J et al. Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc Natl Acad Sci U S A 2011; 108: 9939-9944.
17. Kulke MH, Bergsland EK, Ryan DP et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006; 24: 3555-3561.
18. Decatris M, Santhanam S, O'Byrne K. Potential of interferon-alpha in solid tumours: part 1. BioDrugs 2002; 16: 261-281.
19. Brouty-Boyé D, Zetter BR. Inhibition of cell motility by interferon. Science 1980; 208: 516-518.
20. Ribatti D. Endogenous inhibitors of angiogenesis: a historical review. Leuk Res 2009; 33: 638-644.
21. Tischler AS, Powers JF, Alroy J. Animal models of pheochromocytoma. Histol Histopathol. 2004; 19: 883-895.
22. Potente M, Gerhardt H, Carmeliet P: Basic and therapeutic aspects of angiogenesis. Cell 2011; 146: 873-887.
23. Kawamata T, Yamaguchi T, Shin-ya K et al. Divergence in signaling pathways involved in promotion of cell viability mediated by bFGF, NGF, and EGF in PC12 cells. Neurochem Res 2003; 28: 1221-1225.
24. Raffioni S, Bradshaw RA. Activation of phosphatidylinositol 3-kinase by epidermal growth factor, basic fibroblast growth factor, and nerve growth factor in PC12 pheochromocytoma cells. Proc Natl Acad Sci U S A 1992; 89: 9121-9125.
25. Gill JS, Schenone AE, Podratz JL et al. Autocrine regulation of neurite outgrowth from PC12 cells by nerve growth factor. Brain Res Mol Brain Res 1998; 57: 123-131.
26. Renaud F, Desset S, Oliver L et al. The neurotrophic activity of fibroblast growth factor 1 (FGF1) depends on endogenous FGF1 expression and is independent of the mitogen-activated protein kinase cascade pathway. J Biol Chem 1996; 271: 2801-2811.
27. Groot M, Boxer LM, Thiel G. Nerve growth factor- and epidermal growth factor-regulated gene transcription in PC12 pheochromocytoma and INS-1 insulinoma cells. Eur J Cell Biol 2000; 79: 924-935.
28. Foehr ED, Raffioni S, Fuji R et al. FGF signal transduction in PC12 cells: comparison of the responses induced by endogenous and chimeric receptors. Immunol Cell Biol 1998; 76: 406-413.
29. Berger I, Stahl S, Rychkova N et al. VEGF receptors on PC12 cells mediate transient activation of ERK1/2 and Akt: comparison of nerve growth factor and vascular endothelial growth factor. J Negat Results Biomed 2006; 5: 8.
30. Santhanam S, Decatris M, O'Byrne K. Potential of interferon-alpha in solid tumours: part 2. BioDrugs 2002; 16: 349-372.
31. Hanley JP, Haydon GH. The biology of interferon-alpha and the clinical significance of anti-interferon antibodies. Leuk Lymphoma 1998; 29: 257-268.
32. Barber GN. The interferons and cell death: guardians of the cell or accomplices of apoptosis? Semin Cancer Biol 2000; 10: 103-111.
33. Singh RK, Gutman M, Bucana CD et al. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci U S A 1995; 92: 4562-4566.
34. von Marschall Z, Scholz A, Cramer T et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003; 95: 437-448.
35. Parker EM, Monopoli A, Ongini E et al. Rapamycin, but not FK506 and GPI-1046, increases neurite outgrowth in PC12 cells by inhibiting cell cycle progression. Neuropharmacology 2000; 39: 1913-1919.
36. Giubellino A, Bullova P, Nölting S et al. Combined Inhibition of mTORC1 and mTORC2 Signaling Pathways Is a Promising Therapeutic Option in Inhibiting Pheochromocytoma Tumor Growth: In Vitro and In Vivo Studies in Female Athymic Nude Mice. Endocrinology. 2013; 154: 646-655. Epub 2013 Jan 10.
37. Bridges EM, Harris AL. The angiogenic process as a therapeutic target in cancer. Biochem Pharmacol 2011; 81: 1183-1191.
38. Fong TA, Shawver LK, Sun L et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106.
39. Saito Y, Tanaka Y, Aita Y et al. Sunitinib induces Apoptosis in Pheochromocytoma Tumor Cells by Inhibiting VEGFR2/AKT/mTOR/S6K1 Pathways Through Modulation of Bcl-2 and BAD. Am J Physiol Endocrinol Metab 2012; 302: E615-625.
40. Abdollahi A, Hahnfeldt P, Maercker C et al. Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13: 649-663.
41. Al Ahmad A, Lee B, Stack J et al. Endostatin binds nerve growth factor and thereby inhibits neurite outgrowth and neuronal migration in-vitro. Brain Res 2010; 1360: 28-39.
42. Ziegler CG, Brown JW, Schally AV et. al. Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues. Proc Natl Acad Sci U S A 2009; 106: 15879-1584.